These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

270 related articles for article (PubMed ID: 18680822)

  • 1. [Treatments in the early stage of Parkinson disease].
    Rascol O
    Rev Neurol (Paris); 2008 Apr; 164 Spec No 2():F77-84. PubMed ID: 18680822
    [No Abstract]   [Full Text] [Related]  

  • 2. Recent advances in Parkinson's disease.
    Vécsei L
    Ideggyogy Sz; 2002 Nov; 55(11-12):406-7. PubMed ID: 12632802
    [No Abstract]   [Full Text] [Related]  

  • 3. Treatment challenges in early stage Parkinson's disease.
    Tetrud J
    Neurol Clin; 2004 Oct; 22(3 Suppl):S19-33. PubMed ID: 15501364
    [No Abstract]   [Full Text] [Related]  

  • 4. [Therapeutic strategies recommended for early stage Parkinson's disease].
    Derkinderen P
    Rev Neurol (Paris); 2000; 156 Suppl 2 Pt 2():82-90. PubMed ID: 10916041
    [No Abstract]   [Full Text] [Related]  

  • 5. [What strategies are recommended for early stage disease? Other treatments].
    Damier P
    Rev Neurol (Paris); 2000; 156 Suppl 2 Pt 2():105-8. PubMed ID: 10916044
    [No Abstract]   [Full Text] [Related]  

  • 6. [The early therapy challenge].
    Reichmann H
    Krankenpfl J; 2005; 43(7-10):240. PubMed ID: 16515310
    [No Abstract]   [Full Text] [Related]  

  • 7. Medications for Parkinson's disease.
    Whitney CM
    Neurologist; 2007 Nov; 13(6):387-8. PubMed ID: 18090719
    [No Abstract]   [Full Text] [Related]  

  • 8. When and how should treatment be started in Parkinson disease?
    Lang AE
    Neurology; 2009 Feb; 72(7 Suppl):S39-43. PubMed ID: 19221313
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Reexamination of the TEMPO Study.
    Shults CW
    Arch Neurol; 2005 Aug; 62(8):1320; author reply 1321. PubMed ID: 16087778
    [No Abstract]   [Full Text] [Related]  

  • 10. Neuroprotective agents in Parkinson's disease: clinical evidence and caveats.
    Hälbig TD; Tse W; Olanow CW
    Neurol Clin; 2004 Oct; 22(3 Suppl):S1-S17. PubMed ID: 15501359
    [No Abstract]   [Full Text] [Related]  

  • 11. Peak-dose dyskinesia; an acceptable price for mobility in late-stage Parkinson's disease?
    Wenzelburger R
    Clin Neurophysiol; 2005 Sep; 116(9):1997-8. PubMed ID: 16055380
    [No Abstract]   [Full Text] [Related]  

  • 12. ALS lessons learned from other neurological diseases. Parkinson's disease.
    Fahn S
    Amyotroph Lateral Scler Other Motor Neuron Disord; 2004 Sep; 5 Suppl 1():26-30. PubMed ID: 15512865
    [No Abstract]   [Full Text] [Related]  

  • 13. Preclinical versus clinical neuroprotection.
    Grünblatt E; Schlösser R; Gerlach M; Riederer P
    Adv Neurol; 2003; 91():309-28. PubMed ID: 12442689
    [No Abstract]   [Full Text] [Related]  

  • 14. Disease process and drug treatments in Parkinson's disease.
    Leenders KL
    Eur Neuropsychopharmacol; 2002 Dec; 12(6):575-80. PubMed ID: 12468020
    [No Abstract]   [Full Text] [Related]  

  • 15. "Disease-modification" trials in Parkinson disease: target populations, endpoints and study design.
    Rascol O
    Neurology; 2009 Feb; 72(7 Suppl):S51-8. PubMed ID: 19221315
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Disease-modifying strategies and challenges in PD: interactive breakout sessions.
    Schapira AH
    Neurology; 2003 Sep; 61(6 Suppl 3):S56-63. PubMed ID: 14504381
    [No Abstract]   [Full Text] [Related]  

  • 17. Neuroprotective trials: no longer a cautious optimism.
    Friedman JH
    Med Health R I; 2008 Jun; 91(6):158. PubMed ID: 18610798
    [No Abstract]   [Full Text] [Related]  

  • 18. Can we achieve neuroprotection with currently available anti-parkinsonian interventions?
    Olanow CW
    Neurology; 2009 Feb; 72(7 Suppl):S59-64. PubMed ID: 19221316
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Treatment of degenerative dementia disorders--who should be treated?].
    Hasselbalch SG; Kampmann JP
    Ugeskr Laeger; 2009 Mar; 171(10):802-5. PubMed ID: 19265606
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Possible neuroprotective therapy for Parkinson's disease.
    Ogawa N
    Acta Med Okayama; 1995 Aug; 49(4):179-85. PubMed ID: 7502677
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.